Dermata shifts to OTC dermatology, drops XYNGARI IND

Dermata Therapeutics, Inc. is shifting its strategy to focus on over-the-counter dermatology products that can be sold directly to consumers.

Rhea-AI Filing Summary

Dermata Therapeutics, Inc. is shifting its strategy to focus on over-the-counter dermatology products that can be sold directly to consumers. The company plans to start with a once-weekly acne kit that combines an approved OTC monograph active ingredient with its Spongilla technology, targeting a launch in the middle of 2026, with additional OTC products expected afterward. As part of this pivot into the OTC marketplace, Dermata has withdrawn its investigational new drug application for XYNGARI™ with the U.S. Food and Drug Administration, moving away from that regulated prescription development path.

Insights

Biopharma & Commercial Strategy Analyst

Dermata pivots from prescription drug development to consumer OTC dermatology products.

Dermata Therapeutics is redirecting its efforts toward over-the-counter dermatology products sold directly to consumers. The first focus is a once-weekly acne kit that combines an approved OTC monograph active ingredient with its proprietary Spongilla technology, with a targeted launch in the middle of 2026. This represents a move from a traditional prescription drug model toward a consumer health approach.

The company has also withdrawn its investigational new drug application for XYNGARI™ with the U.S. Food and Drug Administration. Management highlights potential benefits from the OTC shift, including possible acceleration of commercialization, reduced regulatory burden, and access to broader consumer markets, though these outcomes are described as anticipated rather than certain. Execution will depend on successfully developing and marketing OTC products and competing in a crowded consumer dermatology space.

Future company updates may clarify development progress and the specific timing and performance of the planned acne kit launch in the middle of 2026, along with any additional OTC product candidates that follow this initial effort.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What strategic change did Dermata Therapeutics (DRMAW) disclose in this 8-K?

Dermata Therapeutics disclosed a strategic pivot to prioritize the development and distribution of over-the-counter pharmaceutical dermatology products that can be sold directly to consumers, rather than focusing primarily on prescription drug development.

What is Dermata Therapeutics first planned OTC product after this strategic pivot?

The first planned OTC product is a once-weekly acne kit that uses an approved over-the-counter monograph active ingredient together with Dermatas Spongilla technology.

When does Dermata Therapeutics expect to launch its initial OTC acne kit?

Dermata plans to launch its initial once-weekly acne kit in the middle of 2026, with additional OTC product candidates anticipated to follow.

What happened to Dermata Therapeutics investigational new drug application for XYNGARIae?

As part of its strategic shift into the OTC marketplace, Dermata has withdrawn its investigational new drug application for XYNGARIae with the U.S. Food and Drug Administration.

What potential benefits does Dermata expect from shifting to OTC dermatology products?

Dermata cites anticipated benefits from its OTC shift, including a potential acceleration of its path to commercialization, a reduction of regulatory burdens, and expansion into broader consumer markets, although these are described as forward-looking statements subject to risks and uncertainties.

Does this Dermata Therapeutics (DRMAW) disclosure include any financial results or earnings data?

No financial results or earnings data are included in this disclosure; the focus is on Dermatas strategic pivot toward OTC dermatology products and the withdrawal of the XYNGARIae investigational new drug application.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/10/2025 - 08:00 AM Learn about SEC filing dates

false 0001853816 0001853816 2025-09-10 2025-09-10 0001853816 DRMA:CommonStockParValue0.0001PerShareMember 2025-09-10 2025-09-10 0001853816 DRMA:WarrantsExercisableForOneShareOfCommonStockMember 2025-09-10 2025-09-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 10, 2025

DERMATA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-40739		86-3218736
(State or other jurisdiction		(Commission		(IRS Employer
of incorporation)		File Number)		Identification No.)

3525 Del Mar Heights Rd., #322, San Diego, CA		92130
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (858) 800-2543

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol		Name of Each Exchange on Which Registered
Common Stock, par value $0.0001 per share		DRMA		The Nasdaq Capital Market
Warrants, exercisable for one share of Common Stock		DRMAW		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1 933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 8.01. Other Events.

On September 10, 2025, Dermata Therapeutics, Inc. (the “Company”) issued a press release disclosing the Company’s strategic pivot to prioritize the development and distribution of over-the-counter (“OTC”) pharmaceutical dermatology focused products that can be sold directly to consumers. The Company plans to initially focus on developing a once weekly acne kit that utilizes an approved OTC monograph active ingredient along with the Company’s Spongilla technology. The Company plans to launch its initial acne kit in the middle of 2026 with additional product candidates anticipated to follow. As part of the Company’s strategic shift into the OTC marketplace, it has withdrawn its investigational new drug application for XYNGARI™ with the U.S. Food and Drug Administration.

Forward-Looking Statements

This Current Report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “aims,” “anticipates,” “believes,” “could,” “expects,” estimates,” “intends,” “may,” “plans,” “potential,” “projects,” “should,” “will,” and “would,” or similar references to future periods. Examples of forward-looking statements in this Current Report on Form 8-K include, without limitation, statements related to: Dermata’s shift to prioritize OTC dermatology products; the anticipated benefits of the strategic shift; the anticipated benefits of Dermata’s strategic shift to OTC products, including acceleration of its path to commercialization, reduction of regulatory burdens, and expansion into broader consumer markets; the expected timing and success of any planned or future OTC product launches; and other factors described in the Company’s filings with the Securities and Exchange Commission. Any forward-looking statements in this Current Report on Form 8-K are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in or implied by the forward-looking statements, see the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission as well as discussions of potential risks, uncertainties and other important factors in any subsequent Company filings with the Securities and Exchange Commission. All information in this Current Report on Form 8-K is as of the date of the filing; the Company undertakes no duty to update this information unless required by law.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	DERMATA THERAPEUTICS, INC.
Dated: September 10, 2025	By:	/s/ Gerald T. Proehl
	Name:	Gerald T. Proehl
	Title:	Chief Executive Officer